ClinicalTrials.gg
Not yet recruitingNCT07640737BHARAT-3Updated Jun 11, 2026

AUR103 Calcium in Advanced Neuroendocrine Tumours (BHARAT-3 Study)

A Phase 2 interventional study of AUR103 Calcium in Neuroendocrine (NE) Tumors and Advanced NET of GI Origin, sponsored by Aurigene Discovery Technologies Limited. Not yet recruiting at 5 sites in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-06-11.

Sponsored by Aurigene Discovery Technologies Limited (part of Dr. Reddy's Laboratories Limited) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Study summary

A phase 2 Study Evaluating the Efficacy and Safety of Single Agent AUR103 Calcium in Patients with Advanced, Well or Moderately differentiated Neuroendocrine Tumours.

This is a Proof of Concept (PoC) Phase 2 study of AUR103 calcium in patients with advanced, well or moderately differentiated neuroendocrine tumours.

The main objective is to evaluate the efficacy of AUR103 calcium in patients with well or moderately differentiated neuroendocrine tumors.

Patients with relapsed/refractory well or moderately differentiated neuroendocrine tumors.

AUR103 calcium will be administered twice daily. Patients will receive AUR103 calcium until disease progression or intolerable toxicity.

02

Conditions studied

  • Neuroendocrine (NE) Tumors
  • Advanced NET of GI Origin

Browse trials for

Keywords

  • NET Neuroendocrine Tumours
  • Neoplasms
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 30 is below the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Aurigene Discovery Technologies Limited is the lead sponsor of 12 studies on the registry; 4 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 1 (13%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years.
  2. Eastern Coorperative Oncology Group () Performance status of 0 or 1.
  3. confirmed, well or moderately differentiated (G1 or G2), advanced (unresectable or ), neuroendocrine tumour.
  4. Patients should have progressed after at least one .

    Notes:

    1. All previous treatments are allowed
    2. There is no upper limit on the number of prior lines of therapy.
    3. Patient should have received at least one FDA approved therapy for his/her disease (i.e., Patient should have received at least one of everolimus, sunitinib, cabozantinib or Lu177 dotatate for his/her specific NET, as per FDA approved package insert).
    4. SSA (Somatostatin Analogues) alone is not considered a line of therapy for Inclusion criterion 4.
  5. Disease progression with last line of therapy.
  6. by RECISTv1.1.
  7. If the patient is receiving Somatostatin analouges (SSA), the patient should be on stable doses for at least 2 months.

    [Note: Concomitant Somatostatin analouges (SSA) are allowed. No other therapies for NET are allowed along with study drug (e,g., everolimus, sunitinib, cabozantinib, peptide receptor radionuclide therapy (PRRT), chemotherapy etc.)].

  8. Acceptable bone marrow and organ function at screening as described below:

    1. ≥1000/ μL
    2. count ≥ 80,000/μL
    3. ≥ 9 g/dL (Transfusion is allowed to achieve this Hb)
  9. Total ≤ 1.5 x (Patients with known Gilbert's syndrome are allowed with a Total Bilirubin ≤ 2.5 x ULN).
  10. (SGOT) ≤ 3 x ULN (≤ 5 x ULN if known liver metastasis).
  11. ALT (SGPT) ≤ 3 x ULN (≤ 5 x ULN if known liver metastasis).
  12. (CrCl) ≥ 60 mL/min (either measured or estimated by the Cockcroft-Gault formula).

(Note: Cockcroft-Gault formula for estimated creatinine clearance [eCrCl]: eCrCl = [140- Age] × Weight [kg] × [0.85 if Female] / [72 × serum creatinine (mg/dL)]).

-

Exclusion criteria

Exclusion Criteria:

  1. Neuroendocrine carcinoma, such as small cell carcinoma.
  2. Grade 3 neuroendocrine tumours (NET) and/or Poorly differentiated NET.
  3. Patients with known MEN-1 (Multiple Endocrine Neoplasia-1) or MEN-2 (Multiple Endocrine Neoplasia-2) syndromes.
  4. Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral AUR103 calcium.
  5. Systemic anti-cancer therapy, such as small molecule TKIs, mTOR inhibitors, chemotherapy, biological therapy, or immunomodulatory drug therapy, received within the past 28 days or 5 half-lives, whichever is longer, from the Cycle 1 Day 1 of the study.

    [Note: Concomitant use of SSA is allowed].

  6. Patients who have used PRRT as a previous line would require 6 weeks from the last dose, before Cycle 1 Day 1.
  7. Presence of an acute or chronic toxicity resulting from prior anticancer treatment, except for alopecia or nail changes, that has not resolved to Grade ≤ 1, as determined by v 5.0.
  8. Use of any agent within 21 days or 5 half-lives (whichever is longer) prior to Cycle 1 Day 1.
  9. Known symptomatic or untreated or recently treated (≤ 6 months of screening) . Patients with previously treated (> 6 months of screening) brain metastasis and are now stable and asymptomatic, from CNS perspective, are allowed.
  10. Major surgery ≤ 28 days from Cycle 1 Day 1 (major surgery is defined as a procedure requiring general anesthesia).
  11. Hepatic intra-arterial embolization within the last 6 months. Cryoablation or radiofrequency ablation of hepatic within 2 months of randomization.
  12. Presence of any additional within last 3 years, except basal-cell or squamous cell carcinoma of the skin or carcinoma-in situ of the uterine cervix.

    [Note: Patients with other malignancies are eligible if they have remained disease free for at least 2 years prior to trial entry and in the opinion of the investigator deemed to have a low likelihood of recurrence].

  13. Active infection requring systemic therapy. [Note: Prophylactic use of antibiotics is allowed. Any infection detected during screening period which is resolved adequately according to investigator before the Cycle 1 Day 1, is allowed].
  14. Known to be (HIV) positive or have an acquired immunodeficiency syndrome-related illness.
  15. Known active or chronic (HBsAg +ve), infection (HCV antibody +ve).
  16. Expected to require any other form of antineoplastic therapy or targeted therapy while on study.
  17. Uncontrolled congestive heart failure ( [NYHA] Class 2-4), angina, myocardial infarction, cerebrovascular accident, coronary/peripheral artery bypass graft surgery, or , or pulmonary embolism within 3 months prior to Cycle 1 Day 1.
  18. Ongoing cardiac dysrhythmias requiring treatment of any grade or treatment of cardiac dysrhythmias in past 3 months, before Cycle 1 Day 1.
  19. Mean (Fridericia) interval >460 ms on at screening or at Cycle 1 Day 1 pre-dose.
  20. Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or significant gastritis, active bleeding diatheses, presence of any major medical illness (e.g., renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, or psychiatric illness/social situations or laboratory / ECG abnormalities at screening, any or a combination of illnesses), which, in the opinion of the principal investigator (PI), may either put the patient at risk because of participation in the study, or influence the results or the patient's ability to participate in the study.
  21. Current swab-positive or suspected (under investigation) COVID-19 infection or fever and other signs or symptoms suggestive of COVID19 infection with recent contact of person(s) with confirmed COVID19 infection, at screening or Day 1 of Cycle 1.
  22. Positive pregnancy test for women of (WOCBP) at the screening or enrolment visit, or lactating women.
  23. Women of child-bearing potential (WOCBP) who are neither surgically sterilized nor willing to use reliable methods (hormonal contraceptive, IUD, or any double combination of male or female condom, spermicidal gel, diaphragm, sponge, cervical cap).

    -

Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Phase 2 single agent study AUR103 calcium administered as 200 mg or 300 mg twice daily.

    AUR103 Calcium 200mg or 300mg will be administered twice daily

    Drug: AUR103 Calcium

Interventions

  • DrugAUR103 Calcium

    AUR103 Calcium 200mg or 300mg administered twice daily

06

What researchers measure

Primary outcomes

  1. Objective response rate

    Objective response rate (\[ORR\] = CR + PR) by RECISTv1.1.

    Time frame: 3rd week (Days 15-21) of Cycle 2, and thereafter every 2 cycles up till Cycle 6 (i.e., between Day 15-21 of Cycles 4, 6) and then every 3 cycles (i.e., towards the end of Cycle 9, 12). Each treatment cycle will be 28 days in length.

Secondary outcomes

  1. Efficacy: Time to response (TTR)

    Time to respone (TTR) will be assessed during the study

    Time frame: 3rd week (Days 15-21) of Cycle 2, and thereafter every 2 cycles up till Cycle 6 (i.e., between Day 15-21 of Cycles 4, 6) and then every 3 cycles (i.e., towards the end of Cycle 9, 12). Each treatment cycle will be 28 days in length.

  2. Efficacy: Duration of Response (DOR)

    Duration of Response (DOR) will be assessed during the study

    Time frame: 3rd week (Days 15-21) of Cycle 2, and thereafter every 2 cycles up till Cycle 6 (i.e., between Day 15-21 of Cycles 4, 6) and then every 3 cycles (i.e., towards the end of Cycle 9, 12). Each treatment cycle will be 28 days in length.

  3. Efficacy: Stable Disease (SD)

    Sable Disease (SD) will be assessed during the study

    Time frame: 3rd week (Days 15-21) of Cycle 2, and thereafter every 2 cycles up till Cycle 6 (i.e., between Day 15-21 of Cycles 4, 6) and then every 3 cycles (i.e., towards the end of Cycle 9, 12). Each treatment cycle will be 28 days in length.

  4. Efficacy: Clinical Benefit Rate (CBR)

    Duration of Clinical Benefit Rate (CBR) will be assessed during the study

    Time frame: 3rd week (Days 15-21) of Cycle 2, and thereafter every 2 cycles up till Cycle 6 (i.e., between Day 15-21 of Cycles 4, 6) and then every 3 cycles (i.e., towards the end of Cycle 9, 12). Each treatment cycle will be 28 days in length.

  5. Efficacy: Progression Free Survival (PFS)

    Progress Free Survival (PFS) will be assessed during the study

    Time frame: 3rd week (Days 15-21) of Cycle 2, and thereafter every 2 cycles up till Cycle 6 (i.e., between Day 15-21 of Cycles 4, 6) and then every 3 cycles (i.e., towards the end of Cycle 9, 12). Each treatment cycle will be 28 days in length.

  6. Overall Survival (OS)

    Overall Survival (OS) will be assessed during the study

    Time frame: Through study completion, an average of 1 year at the end of cycle 12 or as clinically indicated. Each treatment cycle will be 28 days in length.

  7. Safety and Tolerability of AUR103 calcium

    Safety and tolerability of AUR103 calcium is measured in the study as per the NCI CTCAE 5.0 criteria

    Time frame: 3rd week (Days 15-21) of Cycle 2, and thereafter every 2 cycles up till Cycle 6 (i.e., between Day 15-21 of Cycles 4, 6) and then every 3 cycles (i.e., towards the end of Cycle 9, 12). Each treatment cycle will be 28 days in length.

  8. Pharmacokinetic (PK): Maximum Concentration

    Maximum concentration of AUR103 Calcium

    Time frame: Cycle 1 Day 1 and Cycle 1 Day 15. Blood collection at 9 different time points [pre-dose , 0.5, 1, 2, 3, 4, 6, 8 and 12 hours after morning dose] on Day 1 and Day 15 and 12 hours after the evening dose on Day 1 & Day 15.

  9. Pharmacokinetic (PK): Minimum Concentration

    Minimum concentration of AUR103 calcium

    Time frame: Cycle 1 Day 1 and Cycle 1 Day 15. Blood collection at 9 different time points [pre-dose , 0.5, 1, 2, 3, 4, 6, 8 and 12 hours after morning dose] on Day 1 and Day 15 and 12 hours after the evening dose on Day 1 & Day 15.

  10. Pharmacokinetics (PK): Time to Maximum Concentration

    Time to Maximum concentration of AUR103 Calcium

    Time frame: Cycle 1 Day 1 and Cycle 1 Day 15. Blood collection at 9 different time points [pre-dose , 0.5, 1, 2, 3, 4, 6, 8 and 12 hours after morning dose] on Day 1 and Day 15 and 12 hours after the evening dose on Day 1 & Day 15.

  11. Pharmacokinetics (PK): Terminal elimination half life

    Terminal elimination half-life of AUR103 Calcium

    Time frame: Cycle 1 Day 1 and Cycle 1 Day 15. Blood collection at 9 different time points [pre-dose , 0.5, 1, 2, 3, 4, 6, 8 and 12 hours after morning dose] on Day 1 and Day 15 and 12 hours after the evening dose on Day 1 & Day 15.

07

Study locations

5 sites
08

References and documents

Individual participant data

Plan to share: No — Due to ethical concerns

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Dec 2028, 30 months later.

Of 179 industry-sponsored phase 2 interventional studies under Neoplasms, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 68. This study's planned 30 months is below that.

Counting every sponsor, half of 514 studies reached it within 52 months; a quarter within 33 and three quarters within 92.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2026
First posted
Jun 11, 2026
StartEst.
Jun 30, 2026
Primary completionEst.
Dec 30, 2028
CompletionEst.
Jan 31, 2029
Last update
Jun 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07640737
Responsible party
Sponsor
First posted
Jun 11, 2026
Start date
Jun 30, 2026 (estimated)
Primary completion
Dec 30, 2028 (estimated)
Completion
Jan 31, 2029 (estimated)
Last update
Jun 11, 2026

Study contacts

Akhil Kumar, DM
Contact
akhil_k@aurigene.com
+91 9632203510
Amanchi Swathi
Contact
+91 9010789532

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion